PARP Inhibitor Salt Enhances Solubility and Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using chemotherapy and radiation therapy face resistance due to enhanced DNA repair mechanisms in tumor cells, leading to adverse reactions and reduced therapeutic effectiveness, as tumor cells can survive DNA damage through efficient DNA repair mechanisms.
Innovation Solution
Development of a pharmaceutically acceptable salt of a PARP inhibitor, specifically 4-(3-(4-(1H-imidazo[4,5-b]pyridine-5-yl)piperazine-1-carbonyl)-4-fluorobenzyl) phthalazine-1(dihydro)-one, which forms salts with organic or inorganic acids to enhance solubility and bioavailability, targeting PARP-1 to inhibit DNA repair in tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy or radiation therapy is used to treat cancer, then tumor cells are killed through DNA damage, but tumor cells develop resistance by enhancing DNA repair mechanisms
Solution Approach 1:
The patent introduces PARP inhibitors as intermediary substances that specifically target and inhibit the DNA repair mechanisms in tumor cells. These inhibitors act as mediators between the DNA damage caused by chemotherapy/radiation and the tumor cell death, preventing the repair process that would otherwise allow tumor cells to survive and develop resistance.
Solution Approach 2:
The patent modifies the chemical parameters of the compound by creating different salt forms (hydrochloride, hydrobromide, sulfate, nitrate, perchlorate, tosylate, mesylate salts) of the PARP inhibitor. This parameter change in the chemical state improves solubility and bioavailability, enabling the drug to effectively reach and inhibit PARP enzymes in tumor cells at therapeutic concentrations.
2Reliability
If the dose of therapeutic agent or radiation intensity is increased to overcome tumor resistance, then DNA damage to tumor cells is enhanced, but adverse reactions in normal tissue increase
Solution Approach 1:
PARP inhibitors serve as selective intermediaries that exploit the specific high expression of PARP enzymes in tumor cells with defective DNA repair pathways. This intermediary approach allows for targeted inhibition of DNA repair in tumor cells without requiring excessive doses that would harm normal tissues, thereby maintaining therapeutic effectiveness while reducing adverse reactions.
Solution Approach 2:
The patent converts the harmful DNA repair mechanism that causes resistance into a beneficial target for therapy. By inhibiting PARP enzymes that are overexpressed in tumor cells, the treatment transforms the tumor cells' reliance on efficient DNA repair into a vulnerability, making them more susceptible to DNA damage from chemotherapy and radiation while sparing normal tissues.
3Ease of operation
If solubility and bioavailability of the PARP inhibitor are improved through salt formation, then inhibition of PARP-1 activity is enhanced, but compound complexity increases
Solution Approach 1:
The patent applies parameter changes by transforming the PARP inhibitor compound into different salt forms (hydrochloride, hydrobromide, sulfate, nitrate, perchlorate, tosylate, mesylate salts). This chemical parameter modification significantly improves solubility and bioavailability properties without fundamentally altering the core pharmacological activity of the parent compound, enabling effective drug delivery.
Solution Approach 2:
The patent modifies only specific local properties of the compound by introducing salt-forming groups that enhance solubility and bioavailability, while preserving the intact core structure responsible for PARP inhibition activity. This localized modification approach improves pharmacokinetic properties without complicating the essential mechanism of action.
Data Source
AI summary
The present invention relates to the field of pharmaceutical synthesis, and in particular to an antitumor heterocyclic imidazole compound (I), namely: a pharmaceutical salt of 4-(3-(4-(1H-imidazo[4,5-b]pyridine-5-yl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazine-1(dihydro)-ketone, a preparation method therefor, a pharmaceutical composition thereof and a use thereof in the preparation of antitumor drugs. The pharmaceutical salt of the compound (I) in the present invention may be used in the preparation of a medicament for the treatment or prevention of conditions which can be improved by inhibiting PARP activity.